CytomX Therapeutics (CTMX) Cash from Operations (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Cash from Operations data on file, last reported at 25549000.0 in Q1 2026.

• Quarterly Cash from Operations fell 21.41% year-over-year to 25549000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 80093000.0 (up 1.4% YoY) and the FY2025 annual result came in at 75587000.0, up 12.34% from the prior year.
• Cash from Operations slipped to 25549000.0 in Q1 2026, from 23243000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 9349000.0 in Q1 2023 to a low of 41313000.0 in Q1 2022.
• A 5-year average of 20834705.88 and a median of 21043000.0 in 2025 frame the typical range for Cash from Operations.
• The widest YoY moves for Cash from Operations: up 122.63% in 2023, down 1476.67% in 2023.
• Tracing CTMX's Cash from Operations over 5 years: stood at 1393000.0 in 2022, then tumbled by 1476.67% to 21963000.0 in 2023, then grew by 9.36% to 19908000.0 in 2024, then fell by 16.75% to 23243000.0 in 2025, then retreated by 9.92% to 25549000.0 in 2026.
• The last three Cash from Operations figures came in at 25549000.0 (Q1 2026), 23243000.0 (Q4 2025), and 15548000.0 (Q3 2025), per Business Quant data.